| |
---|
| Detailed Price Information Link |
BACTERIA | How to read the following data (Example) |
Name: | "Moraxella lacunata subsp. lacunata" (Eyre 1900) Lwoff 1939 |
DSM No.: | 18052, Type strain dsm-18052 dsm18052 dsm 18052 Moraxella lacunata subsp. lacunata |
Strain designation: | CIP A182, ATCC 17967, CCUG 4441, NCTC 11011, Morax 260 |
Other collection no. or WDCM no.: | CIP A182,ATCC 17967,CCUG 4441,NCTC 11011 |
Isolated from: | human conjunctivitis |
Country: | France |
Date of sampling: | before 13.03.2006 |
Nagoya Protocol Restrictions: | France requires a benefit-sharing declaration for French genetic resources at the time of utilization, i.e., conducting research. France considers access to genetic resources when utilization begins and not when the initial collection of the material took place and applies to material both in-situ and ex-situ and users within and outside of France.
To comply with French law, you, the user need to make a Declaration regarding access to genetic resources and benefit-sharing arising from your non-commercial utilisation of genetic resources. The steps are the following:
1. File a declaration via the CERFA form n. 15786 (https://www.formulaires.service-public.fr/gf/getAnnexe.do?cerfaAnnexe=1&cerfaFormulaire=15786*02) or by electronic procedure (https://www.demarches-simplifiees.fr/commencer/apa-declaration-pmorale)
2. Await approval by the Ministry for the Ecological Transition, the competent national authority
3. Respond to any requests for more information from the competent national authority
4. Receive an acknowledgment of receipt by the competent national authority certifying the prior informed consent (PIC) and establishment of mutually agreed terms (MAT) regarding benefit-sharing. This procedure shall not exceed 2 months.
For more information about this topic please see the Access and Benefit-Sharing Clearing House: https://absch.cbd.int/en/countries/FR
For more information about the commercial use of this genetic resources please contact: justiziariat@dsmz.de |
History: | <- CIP <- R. Legronx, Inst. Pasteur Paris; Morax 260 |
Cultivation conditions: | Medium 693 , 30°C
Incubation time: 1-2 days
Complete DSMZ Media List |
Summary and additional information: | <- CIP <- R. Legronx, Inst. Pasteur Paris; Morax 260. Human conjunctivitis; France. Type strain. Taxonomy/description (1300, 5518, 10325, 10326). Sequence accession no. AF005160. (Medium 693, 30°C). |
Literature: | 1300, 5518, 10325, 10326 |
Risk group: | 2 (classification according to German TRBA) |
Restrictions: | Act dealing with the prevention & control of infectious diseases in man (Infektionsschutzgesetz), Category A1
|
Supplied as: | Delivery form | | Prices | | Freeze Dried | | 100,- € | Active culture on request | | 240,- € | DNA | | 150,- € | | Price Category for this culture: 1 |
Freight and handling charges will be added. See price list. Note: Freight charges for Risk Group 2 microorganisms will apply. |
Other cultures: | All DSMZ cultures of the species |
| Print data sheet |